Latest peptide research, regulatory updates, and industry news. Your daily source for peptide science developments.
Xianweida ecnoglutide EECOH-2 Lancet publication. Chinese peptide pipeline: Gan & Lee, Xianweida, Wayne Biotech. Capricor deramiocel PDUFA. Hengrui HRS-4729.
Read digest →Amylyx $500.2M closes Friday. Vivani NPM-139 semaglutide implant +20% at 1 year. Chinese Minwei-Innovent GLP-1 progress. Regeneron Pasatru FOP.
Read digest →Amylyx upsizes offering to $500.2M at $35.50/share. Mankind-Chenan insulin India deal. Tolerance Bio licenses NT-I7 IL-7 fusion. Network Bio $50M launch.
Read digest →Amylyx AMLX +48.6% weekly to $35.11 on LUCIDITY, $350M raise, Guggenheim $55/Mizuho $30 PT lifts. Silence closes $201.3M. AMX0318 long-acting follow-on.
Read digest →Amylyx avexitide LUCIDITY hit primary endpoint: 55% hypoglycemic reduction, p<0.001. NDA by end 2026. Aizen $100M AI oral peptide deal. LEO buys dersimelagon.
Read digest →Obesity runners-up (Structure, Amgen, Pfizer) chase Lilly-Novo. Aleniglipron 16.3%. Biogen felzartamab China approval. Frontiers AMP cancer review.
Read digest →Lilly confirms retatrutide Q1 2027 BLA. Cancer peptide vaccine trials +34% YoY. Real-world semaglutide 5.9-12% vs 14.9% STEP-1. PeptiDream new EVPs.
Read digest →Silence closes upsized $175M ADS offering. BridgeBio KKR $406M secondary at $81.21. Retatrutide FDA filing late 2026/2027. CDMO consolidation wave.
Read digest →Ascendis -2.4% Friday despite EPS beat, BioMarin ITC opinion pending. Amylyx LUCIDITY late Aug. Kailera $42.60 PT. Frog AMP review paper.
Read digest →Ascendis Q2 €315M +105% YoY led by YORVIPATH €252M. Kailera ribupatide oral Phase 3 H1 2027. Samsung-PolyPeptide tender prospectus. Novo -6% on Lilly gap.
Read digest →Insilico Medicine BioSpace feature: 31-candidate pipeline, $2.75B Lilly deal. Viking VK3019 Phase 1. Amylyx LUCIDITY readout. Boulevard Bio $65M launch.
Read digest →Hims -6% after hours despite raised Q3 guide. ITM 177Lu-edotreotide gets CRL. Silence SANRECO 88% vs 19% placebo in PV. Rhythm IMCIVREE launch strong.
Read digest →Glutathione is one of the most-sold wellness peptides in the US. You can buy it as pills on Amazon, as an IV drip at a medspa, or as an injectable vial from a compounding pharmacy. The problem: how much of it actually reaches your bloodstream depends heavily on which format you choose. This piece walks through what glutathione is, why bioavailability matters here, and how each format compares.
Semaglutide's registrational trial (STEP-1) reported 14.9% mean weight loss at 68 weeks. Real-world registry and claims analyses report 5.9% to 12% at 6 to 12 months for the same drug in the same doses. This piece walks through what the trials measured, what real-world data shows, why the gap exists, who tends to respond better, and what a buyer can actually expect.
Novo Nordisk has a higher-dose version of Wegovy under FDA review. Semaglutide 7.2 mg once weekly (up from the currently-approved 2.4 mg maximum) produced roughly 19% weight loss in the Phase 3 STEP UP trial, versus roughly 15% for the current 2.4 mg dose. This piece walks through what STEP UP showed, where the FDA review stands, how tolerability changes at higher doses, and how Wegovy 7.2 mg compares to Zepbound and retatrutide for current Wegovy users considering an intensification.